Novo Nordisk's Ozempic Shows Lower Cardiovascular Risk Than Mounjaro…

Event summary

Novo Nordisk's real-world analysis found Ozempic (semaglutide) 2 mg associated with a 6% lower risk of major adverse cardiovascular events (MACE) compared to switching to Mounjaro (tirzepatide) in adults with type 2 diabetes.
The COMPETE SWITCH CV study analyzed claims data for 636,525 adults with type 2 diabetes, comparing outcomes for those escalating to semaglutide 2 mg versus switching to tirzepatide.
Results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy.
The study followed patients for 720 days, with 36.9% escalating to semaglutide 2 mg and 5.7% switching to tirzepatide by the end of the follow-up period.

The big picture

This study adds to the growing body of real-world evidence supporting the cardiovascular benefits of GLP-1 receptor agonists, a critical differentiator in the competitive landscape of type 2 diabetes treatments. Novo Nordisk's findings could influence treatment guidelines and payer decisions, reinforcing the strategic importance of cardiovascular outcomes in diabetes management. The results also highlight the ongoing debate over dose optimization versus therapy switching in chronic disease management.

What we're watching

Competitive Dynamics: How Novo Nordisk will leverage these findings to strengthen Ozempic's market position against Mounjaro in the GLP-1 receptor agonist space.
Regulatory Considerations: Whether the real-world evidence will influence regulatory decisions or reimbursement policies for semaglutide and tirzepatide.
Clinical Adoption: The pace at which healthcare professionals adopt dose escalation strategies for Ozempic based on these cardiovascular outcomes.